This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Blumer, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blumer, J. L.
Related Collections
Right arrow Therapeutics & Toxicology

PEDIATRICS Vol. 104 No. 3 Supplement September 1999, pp. 598-602

Off-Label Uses of Drugs in Children

Jeffrey L. Blumer, PhD, MD

From the Departments of Pediatrics and Pharmacology, Case Western Reserve University, Division of Pediatric Pharmacology and Critical Care, Rainbow Babies and Children's Hospital of University Hospitals of Cleveland, Cleveland, Ohio.

The first 300 words of the full text of this article appear below.

As we approach the new millennium, very little has changed regarding the labeling of prescription drugs for use in infants and children. Along with pregnant women, infants and children remain therapeutic orphans. This condition is understandable because there are very few therapeutic indications that are unique to this patient population and the absolute quantities of drugs required by these patients remains relatively small. On an actuarial basis, humans spend only approximately 16 years as children, whereas they spend another 60 to 80 years as adults. As a result, there is very little incentive for pharmaceutics companies to develop drugs and drug dosing guidelines for infants and children. Careful review has revealed that >70% of all the Physicians' Desk Reference (PDR) entries have either no existing dosing information for pediatric patients or explicit statements that the safety and efficacy in children have not been determined. In the best of circumstances, there are age-specific admonitions because of lack of dosing information for infants and children.

The resulting conundrum can be illustrated best by a case presentation.

    CASE 1

A 6-month-old infant, born 29 weeks premature, presents to a physician's office in respiratory distress. His medical history is significant for developing bronchopulmonary dysplasia as well as for prematurity. Vital signs are temperature: 37.7°C; pulse: 180; respiration: 72; blood pressure: 84/56; physical examination: intercostal retractions, increased anteroposterior diameter, bilateral diffuse expiratory wheezing, nasal flaring; treatment: albuterol 2.5 mg in 2 mL normal saline by nebulization.

While receiving the aerosol, the patient's pulse rate climbs to 215 beats per minutes and he becomes cyanotic despite the O2 used to nebulize the drug. The physician is called by the nurse and witnesses the patient turn black with eyes rolled back. He then suffers a respiratory arrest. Resuscitation is unsuccessful.

When confronted with a similar clinical emergency, most clinicians would have treated the child in the . . . [Full Text of this Article]




This article has been cited by other articles:


Home page
JAMAHome page
H. G. C. Van Spall, A. Toren, A. Kiss, and R. A. Fowler
Eligibility Criteria of Randomized Controlled Trials Published in High-Impact General Medical Journals: A Systematic Sampling Review
JAMA, March 21, 2007; 297(11): 1233 - 1240.
[Abstract] [Full Text] [PDF]


Home page
J Clin PharmacolHome page
A. El-Tahtawy, H. Kokki, and B. E. Reidenberg
Population pharmacokinetics of oxycodone in children 6 months to 7 years old.
J. Clin. Pharmacol., April 1, 2006; 46(4): 433 - 442.
[Abstract] [Full Text] [PDF]


Home page
CLIN PEDIATRHome page
E. Y. Yoon, M. M. Davis, H. El-Essawi, and M. D. Cabana
FDA Labeling Status of Pediatric Medications
Clinical Pediatrics, January 1, 2006; 45(1): 75 - 77.
[PDF]


Home page
Anesth. Analg.Home page
P. F. White
Need Information on "Off-Label" Uses of Anesthetic Drugs? Just Ask the Pharmaceutical Representative!
Anesth. Analg., December 1, 2002; 95(6): 1474 - 1475.
[Full Text] [PDF]


Home page
PediatricsHome page
C. P. F. O'Donnell, R. J. Stone, and C. J. Morley
Unlicensed and Off-Label Drug Use in an Australian Neonatal Intensive Care Unit
Pediatrics, November 1, 2002; 110(5): e52 - 52.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
R. Steinbrook
Testing Medications in Children
N. Engl. J. Med., October 31, 2002; 347(18): 1462 - 1470.
[Full Text] [PDF]